top of page

Press releases

Press releases from odagroup. are primarily issued in English and posted below. As the company is based in Copenhagen, Denmark some local or country-specific press releases might be in danish.

Press release. 2023, 17 Jan.

New SaaS Medicine Reminder service ‘AppHerence’ to revolutionize the way pharmaceutical companies approach patient care and treatment success beyond the pill.

 

Copenhagen - odagroup a leading provider of medicine adherence services, recently announced the launch of a white-labelled app, designed specifically for pharmaceutical companies looking to improve patient experience, adherence, treatment outcomes and generate valuable data and insights.


It’s a well-known fact that simply providing a medication is not enough for proper treatment. Studies such as “Adherence to long-term therapies: evidence for action” by World Health Organization (WHO), have shown that a significant percentage of patients forget to take their medicine or become demotivated, leading to poor treatment outcomes. Another study “Medication Adherence: WHO Cares?” by National Center for Biotechnology Information (NCBI) also highlights the importance of medication adherence in achieving better treatment outcomes. That’s why odagroup place heavy emphasis on “around the pill” strategies as part of its business model, helping Pharma-companies address the barriers that can prevent patients from taking their medicine, including providing educational materials and providing emotional support. odagroup have previously developed the charitable medical companion app DrugStars, which has been downloaded over 600,000 times and has facilitated the distribution of over 65 million doses to users. Built on the company’s extensive experience with drug reminder technology, odagroup now claim to offer one of the most tested, proven, and scientifically validated solutions on the market. The app is fully compliant with all medical device regulations (MDR) and is ready to launch for any patient on any medicine.“DrugStars showed us the importance patient treatment motivation, timely medication reminders for patients and the value of data and insights for pharmaceutical companies,” said Niels Krarup, CEO of odagroup “Decomissioning DrugStars to focus exclusively on ‘AppHerence’ for pharmaceutical partners allow us to address the barriers that can prevent patients from taking their medicine and helps improve treatment adherence while providing insights that in turn help pharmaceutical companies learn and improve. A true win-win model where we believe our service works as a catalyst for the shift towards around the pill strategies to everyones benefit.”

 

About odagroup.
odagroup is a leading digital health consultancy that delivers cutting-edge and regulated technology to support pharmaceutical companies and improve physical and mental wellbeing for patients. Based in Copenhagen, Denmark, and founded in 2019, odagroup work with NGOs, health organizations, insurance companies, and pharmaceutical partners to help more than a million patients world-wide while contributing valuable data to scientific research.The mission is to make the world healthier through modern technology and real-world evidence.

Press release. 2022, 03 Jan.

On January 3, 2022, odagroup announced it has acquired all assets of the bankrupt company, Drugstars. Drugstars is a charitable mobile application that helps individuals remember to take their medication and rewards them for sticking to their regimen. Users can use their rewards to support charitable causes. The app is designed with a simple and user-friendly interface and allows users to track their progress over time. The acquisition by odagroup ensures the continuation of the popular Drugstar app, which is used by over 45,000 active daily users to remind them to take their medication. The new management, in partnership with both former business partners and new players, plans to investigate opportunities for creating a sustainable and scalable business model. However, they assure users that the app will continue to be free and ad-free.

bottom of page